Researchers Used AI to Find a Side Effect-Free Ozempic Alternative Your Body Has Been Making All Along

A team at Stanford Medicine has discovered a potential side-effect-free alternative to Ozempic and Wegovy using artificial intelligence. The molecule, called BRP (BRINP2-related peptide), is a naturally occurring 12-amino-acid peptide that suppressed appetite and reduced food intake by up to 50% in animal studies without causing nausea, constipation, or muscle loss. The research, published in *Nature* in March 2025, found BRP acts specifically on the hypothalamus, unlike semaglutide—the active ingredient in Ozempic and Wegovy—which binds to receptors across multiple organ systems, contributing to widespread side effects. BRP was identified using an AI tool called Peptide Predictor, which analyzed over 2,600 uncharacterized human peptide fragments. Unlike GLP-1 agonists, BRP targets a distinct metabolic pathway, offering a more targeted approach to appetite regulation. In lean mice and minipigs, a single injection of BRP before feeding reduced food intake by up to 50% within an hour, with no reported nausea, food aversion, or muscle loss. The discovery comes as growing numbers of GLP-1 drug users report severe side effects. A 2025 RAND Corporation survey of 8,793 U.S. adults found half experienced nausea and a third suffered diarrhea, while a 2026 University of Pennsylvania analysis of 400,000 Reddit posts revealed 44% of users reported at least one side effect. Reproductive symptoms, including menstrual irregularities, were also noted as underreported concerns, particularly among women. BRP remains preclinical and has not been tested in humans or reviewed by the FDA. Stanford Medicine expects human trials in the near future, though drug development typically takes years. The 50% food intake reduction observed in animals was measured over one hour post-injection, not across long-term use. Additionally, lead researchers Katrin Svensson and Laetitia Coassolo hold patents related to BRP, indicating potential commercial interests in its development. The findings raise hope for a new class of weight-loss treatments that avoid the debilitating side effects of current GLP-1 drugs. However, widespread availability remains years away, pending clinical trials and regulatory approval.